Incretin ReviewResearch · Context · Care

Publication record

The source record

Official pages, original research and clearly identified evidence limits.

Source notes

Checked October 5, 2026. Provider pages document advertised terms. Study summaries identify the scope of our review.

  1. Lincoff et al. — SELECT cardiovascular outcomes trialOriginal randomized trial; abstract reviewed
  2. FDA — AEMS Public Dashboard FAQPublic safety-data limitations
  3. FDA — interpreting postmarket safety surveillanceRegulatory surveillance explanation
  4. FDA — concerns with unapproved GLP-1 drugsRegulatory and safety context
  5. FDA — compounding questions and answersCompounded-product status
  6. CoreAge Rx — semaglutide offerProvider advertisement
  7. CoreAge Rx — tirzepatide offerProvider advertisement
  8. CoreAge Rx — pricing and plansProvider billing terms
  9. SuperHealthy Rx — GLP-1 offerProvider advertisement
  10. Likeness Rx — GLP-1 plansProvider offer and renewal terms
  11. Ro — Body membershipProvider membership advertisement
  12. WeightWatchers — Med+ programProvider membership advertisement
  13. LillyDirect — access optionsManufacturer access program